Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes

Cited by (793)

Items 401–500 of 793

1. Examining the Association of Olmesartan and Other Angiotensin Receptor Blockers With Overall and Cause-Specific Mortality
   Jou‐Wei Lin, Chia‐Hsuin Chang, James L. Caffrey, Li‐Chiu Wu, Mei‐Shu Lai · 2014 · Hypertension
2. New clinical concepts after the ONTARGET trial
   Luis Miguel Ruilope, J. Segura, José Luis Zamorano · 2011 · Expert Review of Cardiovascular Therapy
3. Determining the Optimal Protocol for Measuring an Albuminuria Class Transition in Clinical Trials in Diabetic Kidney Disease
   Tobias F. Kröpelin, Dick de Zeeuw, Giuseppe Remuzzi, Rudy Bilous, Hans‐Henrik Parving, Hiddo J.L. Heerspink · 2016 · Journal of the American Society of Nephrology
4. Effect of valsartan on kidney outcomes in people with impaired glucose tolerance
   Gemma E. Currie, Mary Angelyn Bethel, Björn Holzhauer, Steven M. Haffner, Rury R. Holman, John J.V. McMurray · 2017 · Diabetes Obesity and Metabolism
5. Associations between angiotensinogen M235T polymorphisms and the risk of diabetic nephropathy: A meta-analysis
   Bo Zhou, Min Wen, Ling Mi, Cu-Jiao Hu, Yi Zhang, Jian-Tar Wang, Lei Tang · 2018 · Diabetes Research and Clinical Practice
6. The effects of a participatory structured group educational program on the development of CKD: a population-based study
   Tadashi Sofue, Yuka Okano, Nao Matsushita, Masahiro Moritoki, Yoko Nishijima, Hiroshi Fujioka, Yasushi Yamasaki, Masahito Yamanaka, Akira Nishiyama, Tetsuo Minamino · 2019 · Clinical and Experimental Nephrology
7. Antihypertensive Efficacy of Olmesartan Medoxomil and Ramipril in Elderly Patients with Mild to Moderate Hypertension Grouped According to Renal Function Status
   the ESPORT Study Group, Ettore Malacco, Stefano Omboni, Jean-Michel Mallion, Massimo Volpe · 2012 · High Blood Pressure & Cardiovascular Prevention
8. End-Organ Protection in Patients with Hypertension
   Giuliano Tocci, Massimo Volpe · 2011 · Drugs
9. Hypertension and Diabetic Nephropathy
   Jeppe Skov, Jens Sandahl Christiansen, Per Løgstrup Poulsen · 2016 · Endocrine development
10. Bloqueo del sistema renina-angiotensina-aldosterona en pacientes con enfermedad renal diabética avanzada
    Sheila Bermejo, Carles Oriol García, Eva Rodríguez, Clara Barrios, Sol Otero, Sergi Mojal, Julio Pascual, María José Soler · 2017 · Nefrología
11. suPAR: A Cardiac Biomarker With a Future?
    Yaron Arbel, Bradley H. Strauss · 2015 · Canadian Journal of Cardiology
12. Urinary Markers in Heart Failure – Types, Timing and Thresholds. European Journal of Heart Failure Expert Consensus Document
    Masatake Kobayashi, Biykem Bozkurt, Peder Langeland Myhre, Juan Carlos López‐Azor, Mateusz Guzik, Gracjan Iwanek, Guillaume Baudry, Marta Cobo Marcos, Òscar Miró, Jeroen Dauw et al. · 2025 · European Journal of Heart Failure
13. DAPagliflozin for the attenuation of albuminuria in Patients with hEaRt failure and type 2 diabetes (DAPPER study): a multicentre, randomised, open-label, parallel-group, standard treatment-controlled trial
    Fumiki Yoshihara, Miki Imazu, Ichiro Sakuma, Yukio Hiroi, Hisao Hara, Osamu Okazaki, Chizuru Ishiguro, Chisato Izumi, Teruo Noguchi, Toshihiko Shiraiwa et al. · 2023 · EClinicalMedicine
14. Comparison of Azelnidipine and Trichlormethiazide in Japanese Type 2 Diabetic Patients with Hypertension: The COAT Randomized Controlled Trial
    Masahiro Takihata, Akinobu Nakamura, Yoshinobu Kondo, Satsuki Kawasaki, Mari Kimura, Yasuo Terauchi · 2015 · PLoS ONE
15. The ROADMAP trial: olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes
    Guido M. Grassi · 2011 · Expert Opinion on Pharmacotherapy
16. Albuminuria in hypertension
    Yao‐Ping Lin · 2013 · Hypertension Research
17. Complete Renin–Angiotensin–Aldosterone System (RAAS) Blockade in High-Risk Patients
    Sanjay Rajagopalan, George L. Bakris, William T. Abraham, Bertram Pitt, Robert D. Brook · 2013 · Hypertension
18. Antihypertensive therapy for the prevention of nephropathy in diabetic hypertensive patients
    Alex N. Isaacs, Ashley H. Vincent · 2016 · Journal of Clinical Pharmacy and Therapeutics
19. The Effect of Resting Heart Rate on the New Onset of Microalbuminuria in Patients With Type 2 Diabetes
    Roland Erich Schmieder, Peter Bramlage, Hermann G. Haller, Luis Miguel Ruilope, Michael Böhm · 2016 · Medicine
20. Attitudes and preferences for the clinical management of hypertension and hypertension-related cerebrovascular disease in the general practice: results of the Italian hypertension and brain survey
    Giuliano Tocci, Arrigo F.G. Cicero, Massimo Salvetti, Beatrice Musumeci, Andrea Ferrucci, Claudio Borghi, Massimo Volpe · 2017 · Clinical Hypertension
21. Olmesartan combined with renal denervation reduces blood pressure in association with sympatho-inhibitory and aldosterone-reducing effects in hypertensive mice with chronic kidney disease
    Masaaki Nishihara, Ko Takesue, Yoshitaka Hirooka · 2018 · Clinical and Experimental Hypertension
22. Prognostic factors in pediatric pneumococcal meningitis patients in mainland China: a retrospective multicenter study
    Caiyun Wang, Hongmei Xu, Jikui Deng, Hui Yu, Yiping Chen, Shifu Wang, Wei‐Chun Huang, Jianhua Hao, Chun Wang, Huiling Deng et al. · 2019 · Infection and Drug Resistance
23. Olmesartan Medoxomil, An Angiotensin II-Receptor Blocker, Ameliorates Renal Injury In db/db Mice
    Ye Zhu, Zeliang Li, Ao Ding, Hui Yang, Zhu Wei-ping, Tongxia Cui, Huitao Zhang, Hua Zhang · 2019 · Drug Design Development and Therapy
24. Doença renal do diabetes
    João Roberto de Sá, Érika Bevilaqua Rangel², Andréa Carla Bauer, Carolina de Castro Rocha Betônico, Themis Zelmanovitz, Ana Flávia de Souza Moura, Sandra Pinho Silveiro, Luís Henrique Santos Canani, Márcio Weissheimer Lauria, Rodrigo Nunes Lamounier et al. · 2022 · Conectando Pessoas eBooks
25. Recent advances in the pharmacotherapeutic management of diabetic kidney disease
    Tomasz J. Block, Duygu Batu, Mark Emmanuel Cooper · 2022 · Expert Opinion on Pharmacotherapy
26. Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors
    Anthony T. P. Chan, Sydney C.W. Tang · 2022 · Kidney Research and Clinical Practice
27. Benefit of Blood Pressure Control in Diabetic Patients
    Ulrich Kintscher · 2015 · Current Hypertension Reports
28. Dilemmas of Blood Pressure Management for Heart Failure Prevention
    Vasiliki V. Georgiopoulou, Andreas P. Kalogeropoulos, Javed Butler · 2011 · Circulation Heart Failure
29. Value of Angiotensin Receptor Blocker Therapy in Diabetes
    Joseph L. Izzo, Adrienne S. Zion · 2011 · Journal of Clinical Hypertension
30. La protection cardiovasculaire du patient diabétique avec maladie rénale chronique et cas particulier de l’insuffisance rénale chronique terminale du sujet âgé
    Philippe Zaoui, Thierry P. Hannedouche, Christian Combe · 2017 · Néphrologie & Thérapeutique
31. Treatment of Diabetic Kidney Disease With Hypertension Control and Renin Angiotensin System Inhibition
    Vikram Patney, Kunal R. Chaudhary, Adam T. Whaley‐Connell · 2018 · Advances in Chronic Kidney Disease
32. World Kidney Day 2020: Advances in Preventive Nephrology
    Jia Liang Kwek, Terence Yi Shern Kee · 2020 · Annals of the Academy of Medicine Singapore
33. Diabetische Nephropathie
    Alexander Sämann, Günter Wolf · 2012 · Der Internist
34. Attitudes and preferences for the clinical management of hypertension and hypertension-related cardiac disease in general practice: results of the Italian Hypertension and Heart Survey
    Giuliano Tocci, Arrigo F.G. Cicero, Massimo Salvetti, Pietro Francia, Andrea Ferrucci, Claudio Borghi, Massimo Volpe · 2014 · Journal of Human Hypertension
35. Linking Diabetic Complications to Sorbitol Oxidation, Oxidative Stress and Metabolic Suppression
    Joseph R. Williamson · 2012 · Journal of Diabetes & Metabolism
36. Predictors of proteinuria reduction by monotherapy with an angiotensin receptor blocker, olmesartan
    Minamo Ono, Michio Fukuda, Toshiyuki Miura, Masashi Mizuno, Yoko Kato, Ryo Sato, Takehiro Naito, Hiroyuki Togawa, Yuji Sasakawa, Tatsuya Tomonari et al. · 2012 · Journal of the Renin-Angiotensin-Aldosterone System
37. Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study
    M. Kojima, S. Okubo, Ryuichi Mizubayashi, Naoki Isaka, H. Machida, Shinya Okamoto, Hiroko HIROTA, M. Takeuchi, T. Kato, Kaname Nakatani et al. · 2013 · Nephrology Dialysis Transplantation
38. The effect of achieving a systolic blood pressure of 140mmHg. A prospective study of ambulatory measurements in type 2 diabetic patients with nephropathy
    Ole Torffvit · 2012 · Journal of Diabetes and its Complications
39. Telmisartan plus amlodipine single-pill combination for the management of hypertensive patients with a metabolic risk profile (added-risk patients)
    Ludwin Ley, Helmut Schumacher · 2012 · Current Medical Research and Opinion
40. Current and Future Treatment of Hypertension in the Sprint Era
    Robert A. Phillips · 2015 · Methodist DeBakey Cardiovascular Journal
41. A Stepped Care Approach to the Management of Chronic Kidney Disease
    Damian G. Fogarty, Maarten W. Taal · 2012 · Elsevier eBooks
42. A crossover comparison of urinary albumin excretion as a new surrogate marker for cardiovascular disease among 4 types of calcium channel blockers
    Tadashi Konoshita, Yasukazu Makino, Tomoko Kimura, Miki Fujii, Norihiro Morikawa, Shigeyuki Wakahara, Kenichiro Arakawa, Isao Inoki, Hiroyuki Nakamura, Isamu Miyamori · 2011 · International Journal of Cardiology
43. Prevention of Coronary Artery Disease: Recent Advances in the Management of Hypertension
    Chiara Recarti, Thomas Unger · 2013 · Current Atherosclerosis Reports
44. Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination
    Henry A. Punzi · 2011 · Integrated Blood Pressure Control
45. Blood Pressure-Independent Effect of Olmesartan on Albuminuria in Mice Overexpressing Renin
    Hiroaki Ichikawa, Ikuyo Narita, Masato Narita, Tomohiro Tanno, Yoshikazu Yokono, Yoshihiro Kimura, Μakoto Tanaka, Tomohiro Osanai, Ken Okumura, Hirofumi Tomita · 2018 · International Heart Journal
46. Optimal blood pressure for the prevention of hypertensive nephropathy in nondiabetic hypertensive patients in Taiwan
    Ting‐Wei Kao, Chin‐Chou Huang, Jaw‐Wen Chen · 2020 · Journal of Clinical Hypertension
47. A Prospective Randomized, Double-Blind, Multi-Center, Phase III Clinical Trial Evaluating the Efficacy and Safety of Olmesartan/Amlodipine plus Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Dyslipidemia: A LEISURE Study
    Sang‐Ho Jo, Seok‐Min Kang, Byung‐Su Yoo, Young Soo Lee, Ho‐Joong Youn, Kyung Wan Min, Jae Myung Yu, Hyun Ju Yoon, Woo Shik Kim, Gee-Hee Kim et al. · 2022 · Journal of Clinical Medicine
48. Microalbuminuria y excreción urinaria de albúmina en la práctica clínica
    Rodrigo Tagle, Fernando González, Mónica Acevedo B · 2012 · Revista médica de Chile
49. Effects of pharmacist participation in chronic kidney disease (CKD) network and CKD manual distribution on drug‐related kidney injury
    Tatsuo Yamamoto, Isao Nakayama, Yutaro Kawakatsu, Takumi Yamamoto, Naoyuki Ishigami, Kei Watanuki, Takayoshi Okabe, Hidetarou Yokoyama · 2019 · Pharmacoepidemiology and Drug Safety
50. Olmesartan, Microalbuminuria, and Type 2 Diabetes
    Alexander Lammert, Bernhard K Krämer, Bernd Krüger · 2011 · New England Journal of Medicine
51. Randomised controlled trials of antihypertensive therapy: does exclusion of orthostatic hypotension alter treatment effect? A systematic review and meta-analysis
    Catriona Reddin, Robert Murphy, Caoimhe Hanrahan, Elaine A. Loughlin, John P. Ferguson, Conor S. Judge, R Waters, Michelle D. Canavan, Rose Anne Kenny, Martin James O'Donnell · 2023 · Age and Ageing
52. Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?
    Vivencio Barrios, Carlos Escobar · 2013 · Expert Opinion on Pharmacotherapy
53. SPRINT in context
    Mattias Brunström, Bo Carlberg · 2018 · Journal of Hypertension
54. Duration of diabetes as an important risk factor of microalbuminuria in type 2 diabetes
    Vitasari Indriani, Tri Lestari, Vidya Dewantari · 2020 · Universa Medicina
55. Short Term Safety and Tolerability of a Fixed Dose Combination of Olmesartan, Amlodipine and Hydrochlorothiazide
    Jagdish Chander Mohan · 2015 · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH
56. Single Anti-Platelet Therapy versus Dual Anti-Platelet Therapy after Transcatheter Aortic Valve Replacement: A Meta-Analysis
    Ahmed Abuzaid, Pragya Ranjan, Carly A. Fabrizio, Kevin D. Felpel, Raveen Chawla, Adrienne Topic, Islam Y. Elgendy · 2018 · Structural Heart
57. Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes
    Cristina Saavedra, Jorge Barriuso, Mairead Geraldine McNamara, Juan W. Valle, Ángela Lamarca · 2019 · Cancer Management and Research
58. The role of angiotensin receptor blockers in CVD risk management
    Leonardo Grabinski Bottino, Flávio Danni Fuchs · 2020 · Expert Review of Cardiovascular Therapy
59. Awareness of Physicians in Yemen Toward High Blood Pressure Management According to the Eighth Joint National Committee (JNC 8) Guideline
    Abdulsalam M. Halboup, Gamil Qasem Othman, Mohammed Battah, Karem Hasan Alzoubi, Hebah Sallom · 2020 · International Journal of General Medicine
60. Drug development: how academia, industry and authorities interact
    Silvio K. Garattini, Norberto Perico · 2014 · Nature Reviews Nephrology
61. Cardiovascular outcomes with antihypertensive therapy in type 2 diabetes: an analysis of intervention trials
    George Jerums, Sianna Panagiotopoulos, Elif Ilhan Ekinci, R. J. MacIsaac · 2015 · Journal of Human Hypertension
62. Identification of the Stages of Diabetic Nephropathy at Which Angiotensin II Receptor Blockers Most Effectively Suppress Albuminuria
    Susumu Ogawa, Masato Matsushima, Takefumi Mori, Masashi Okamura, Miho Senda, Takuya Sakamoto, Kazuhiro Nako, Sadayoshi Ito · 2013 · American Journal of Hypertension
63. Statins and beyond: Concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes
    Eberhard Standl · 2012 · Diabetes and Vascular Disease Research
64. A Review of Current Evidence of Olmesartan Medoxomil Mimicking Symptoms of Celiac Disease
    Michele L. Sanford, Angela K. Nagel · 2014 · Journal of Pharmacy Practice
65. The Significance of the J-Curve in Hypertension and Coronary Artery Diseases
    Chang Gyu Park, Ju Young Lee · 2011 · Korean Circulation Journal · Retracted
66. The benefit of angiotensin AT1 receptor blockers for early treatment of hypertensive patients
    Bruno Trimarco, Ciro Santoro, Marco Pepe, Maurizio Galderisi · 2017 · Internal and Emergency Medicine
67. Kidney-accumulating olmesartan-loaded nanomicelles ameliorate the organ damage in a murine model of Alport syndrome
    Sang Heon Suh, Ansuja Pulickal Mathew, Hong Sang Choi, Arathy Vasukutty, Chang Seong Kim, In Jin Kim, Seong Kwon, Soo Wan Kim, In‐Kyu Park, Eun Hui Bae · 2021 · International Journal of Pharmaceutics
68. Why albuminuria should be assessed more frequently in everyday clinical practice? Position statement
    Piotr Dobrowolski, Andrzej Januszewicz, Janusz Gumprecht, Jolanta Małyszko, Krzysztof Narkiewicz, Tomasz P. Stompór, Andrzej Tykarski, Andrzej Więcek, Andrzej Prejbisz · 2021 · Polskie Archiwum Medycyny Wewnętrznej
69. CCR2 inhibition: a panacea for diabetic kidney disease?
    Matthew R Weir · 2015 · The Lancet Diabetes & Endocrinology
70. Kidney Disease in Diabetes
    2020 · Diabetes : current and future developments
71. What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?
    Alejandro de la Sierra, Jorge Brenes Salazar · 2011 · Advances in Therapy
72. Reducing the Cardiovascular Disease Burden
    Behnood Bikdeli, José Augusto Barreto‐Filho · 2012 · Circulation Cardiovascular Quality and Outcomes
73. Prevalence, incidence and risk factors of chronic kidney disease in people with diabetes and hypertension, and the prognosis and kidney function decline in Indonesia: a multicentre cross-sectional study in primary care centres
    Ni Made Hustrini, Endang Susalit, Kuntjoro Harimurti, Ira Susanti Haryoso, Adriana Eunike Legrans, Kirana Damarjati, Sitri Minangsih, Lida Nurhisan, Ma’mun Zaini, Sendy Oktavianti et al. · 2025 · BMJ Open
74. An easy-to-operate web-based calculator for predicting the progression of chronic kidney disease
    Qian Xu, Yunyun Wang, Yiqun Fang, Shanshan Feng, Cuiyun Chen, Yanxia Jiang · 2021 · Journal of Translational Medicine
75. From Hypertension to Beyond: Unraveling the Diverse Mechanisms of Olmesartan in Disease Modulation
    Laiba Rind, Tarique Mahmood, Mohammed Haris Siddiqui, Farogh Ahsan, Arshiya Shamim, Aamir Anwar, Rajnish Kumar Yadav · 2024 · Drug Research
76. Machine-learning clustering analysis identifies novel phenogroups in patients with ST-elevation acute myocardial infarction
    Andrija Matetić, Theocharis Kyriacou, Mamas A. Mamas · 2024 · International Journal of Cardiology
77. PREVENTING DIABETIC KIDNEY DISEASE: A SYSTEMATIC REVIEW OF CURRENT PHARMACOLOGICAL APPROACHES
    B Dharani, STEPHY SEBASTIAN, Shermin Nazrin, A SUBA · 2025 · International Journal of Applied Pharmaceutics
78. Comparative efficacy of different antihypertensive drug classes for stroke prevention: A network meta-analysis of randomized controlled trials
    Ding Yu, Junxia Li, Yuan Cheng, Handong Wang, Xindi Ma, Tao Ding, Zhong‐ning Zhu · 2025 · PLoS ONE
79. Diabetische Nephropathie – Update 2012
    Martin Auinger, Roland Edlinger, Friedrich C. Prischl, Alexandra Kautzky‐Willer, Rudolf Prager, Alexander R. Rosenkranz, Michael Roden, Marcus D. Säemann, Martin Clodi, Guntram Schernthaner · 2012 · Wiener klinische Wochenschrift
80. Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials
    Magnus Baumhäkel, Böhm · 2011 · Vascular Health and Risk Management
81. Antihypertensive Therapie bei Diabetes mellitus
    Guntram Schernthaner, Heinz Drexel, Alexander R. Rosenkranz, Gerit-Holger Schernthaner, Bruno Watschinger · 2012 · Wiener klinische Wochenschrift
82. Do Fixed Dose Combinations Play an Important Role in the Management of Coexistent Type Two Diabetes Mellitus and Hypertension?
    Nisharani Sudhakar Ranpise, Preeti Jamkar, Harshada Langote · 2015 · Indian Journal of Pharmaceutical Education and Research
83. Prevention of electrocardiographic left ventricular remodeling by the angiotensin receptor blocker olmesartan in patients with type 2 diabetes
    Ulrike Raff, Christian Ott, Luis Miguel Ruilope, Jan Menne, Hermann G. Haller, Roland Erich Schmieder · 2014 · Journal of Hypertension
84. Achievement of recommended glucose and blood pressure targets in patients with type 2 diabetes and hypertension in clinical practice -- study rationale and protocol of DIALOGUE
    Anselm Kai Gitt, Roland Erich Schmieder, E D Dütting, Peter Bramlage, Steffen Schneider, Diethelm Tschöpe · 2012 · Cardiovascular Diabetology
85. Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria
    Roberto Fogari, Amedeo Mugellini, Annalisa Zoppi, Paola Stefania Preti, Pamela Maffioli, Tiziano Perrone, Giuseppe Derosa · 2013 · Expert Opinion on Pharmacotherapy
86. An evaluation of the latest evidence relating to renin–angiotensin system inhibitors
    Carlos Escobar, Vivencio Barrios · 2013 · Expert Opinion on Drug Metabolism & Toxicology
87. Changes in blood pressure classification, blood pressure goals and pharmacological treatment of essential hypertension in medical guidelines from 2003 to 2013
    Tam Tran, Nhat Minh Giang · 2014 · IJC Metabolic & Endocrine
88. Emerging drug combinations to optimize renovascular protection and blood pressure goals
    Vivencio Barrios · 2012 · International Journal of Nephrology and Renovascular Disease
89. Pharmacologic Management of Hypertension
    Joseph J. Saseen · 2012 · Elsevier eBooks
90. Should We Still Believe in Randomized Controlled Trials in Nephrology?
    Monica Cortinovis, Norberto Perico, Giuseppe Remuzzi · 2016 · The Nephron journals/Nephron journals
91. Comprehensive Care for People With Diabetic Kidney Disease
    Koyal Jain, Amy K. Mottl · 2015 · Diabetes Spectrum
92. The impact of antihypertensives on kidney disease
    Diego Francisco Márquez, Gema Ruiz‐Hurtado, Luis Miguel Ruilope · 2017 · F1000Research
93. A Primer on Quality Assurance and Performance Improvement for Interprofessional Chronic Kidney Disease Care: A Path to Joint Commission Certification
    Linda Awdishu, Teri Moore, Michelle Morrison, Christy Turner, Danuta Trzebinska · 2019 · Pharmacy
94. Combination therapy in the extended cardiovascular continuum
    Claudio Borghi, Martino Morbini, Arrigo F.G. Cicero · 2015 · Journal of Cardiovascular Medicine
95. Early diagnostic of diabetic foot using thermal images
    Luis Alberto Vilcahuaman Cajacuri · 2013 · theses.fr (ABES)
96. Asian Pacific Society of Nephrology Clinical Practice Guideline on Diabetic Kidney Disease—2025 Update
    Adrian Liew, Sunita Bavanandan, Chuan‐Ming Hao, Soo Kun Lim, Narayan Prasad, Manisha Sahay, Paweena Susantitaphong, Veena Roberts, Eranga Sanjeewa Wijewickrama, Muh Geot Wong et al. · 2025 · Nephrology
97. Cardiovascular outcomes in patients with diabetes when initiating blood pressure lowering at baseline SBP between 130 and 140 mm Hg: A meta‐analysis
    Shifei Wang, Nima Moumin Djama, Yanxian Lai, Hairui Li, Wangjun Liao, Yulin Liao, Jianping Bin · 2019 · Journal of Clinical Hypertension
98. Controversies in blood pressure goal guidelines and masked hypertension
    Robert A. Phillips · 2012 · Annals of the New York Academy of Sciences
99. Food-Derived Bioactive Peptides: A Promising Substitute to Chemosynthetic Drugs Against the Dysregulated Renin-Angiotensin System in COVID-19 Patients
    A.G.M.Sofi Uddin Mahamud, Md. Ehsanul Kabir, Abdullah Al Mamun Sohag, Chong Chen, Md. Abdul Hannan, Mahmudul Hasan Sikder, Keshab Bhattarai, Bikash Baral, Md Jamal Uddin · 2021 · Journal of Biologically Active Products from Nature
100. Are there new threshold and goals in the treatment of arterial hypertension?
     J. Segura, Luis Miguel Ruilope · 2012 · European Journal of Clinical Investigation